KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Change in Receivables: 2010-2024

Historic Change in Receivables for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to -$2.1 million.

  • Supernus Pharmaceuticals' Change in Receivables rose 200.64% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 29.89%. This contributed to the annual value of -$2.1 million for FY2024, which is 88.93% up from last year.
  • According to the latest figures from FY2024, Supernus Pharmaceuticals' Change in Receivables is -$2.1 million, which was up 88.93% from -$18.8 million recorded in FY2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Change in Receivables peaked at $34.6 million during FY2020, and registered a low of -$18.8 million during FY2023.
  • Over the past 3 years, Supernus Pharmaceuticals' median Change in Receivables value was -$2.1 million (recorded in 2024), while the average stood at -$1.5 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first surged by 523.22% in 2022, then plummeted by 214.66% in 2023.
  • Supernus Pharmaceuticals' Change in Receivables (Yearly) stood at $34.6 million in 2020, then plummeted by 111.17% to -$3.9 million in 2021, then spiked by 523.22% to $16.4 million in 2022, then tumbled by 214.66% to -$18.8 million in 2023, then soared by 88.93% to -$2.1 million in 2024.